Pharma News

Biocon Pharma Limited, has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India, CDSCO (Central Drugs Standard Control Organisation).

U.S. Food and Drug Administration approval of a New Drug Application for KHINDIVI hydrocortisone Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency.

GSK plc announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype.

A new study reveals the biological secret to the Zika virus’s infectious success : Zika uses host cells own self-care system of clearing away useless molecules to suppress the host proteins that the virus has employed to get into those cells in the first place.

T cells are front line defenders against pathogens, like viruses, and cancer because they can kill infected or malignant cells. Scientists have for years been trying different techniques to direct these immune cells to protect against disease. CAR-T therapy is one such example of prompting the body’s own immune system to attack certain forms of cancer using T cells

Researchers at Weill Cornell Medicine have discovered how a parasite that causes malaria when transmitted through a mosquito bite can hide from the body’s immune system, sometimes for years. It turns out that the parasite, Plasmodium falciparum, can shut down a key set of genes, rendering itself immunologically invisible.

In a new article published in Nature communications, researchers from Uppsala Antibiotic Center, Uppsala University and SciLifeLab describe a fundamental mechanism of antibiotic resistance. What happens in a bacterium that is resistant to the antibiotic fusidic acid? With a stop-motion movie at the atomic level, they can show that the resistance protein FusB works nearly like a crowbar.

Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Brekiya dihydroergotamine mesylate injection, the first and only dihydroergotamine autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

A study published in the Journal of Medicinal Chemistry presents a new family of candidate compounds for the treatment of Alzheimer’s disease and pain, which have shown promising effects in animal models.